Cargando…

Increased c‑SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma

Lenvatinib, a multi-kinase inhibitor, serves a crucial role in the treatment of unresectable hepatocellular carcinoma (HCC). However, >50% of patients receiving lenvatinib therapy experience tumor growth or metastasis within 1 year, highlighting the need to address acquired resistance as a critic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Masamitsu, Araki, Takuya, Yashima, Hideaki, Nagamine, Ayumu, Nagano, Daisuke, Yamamoto, Koujirou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654551/ https://www.ncbi.nlm.nih.gov/pubmed/38020292 http://dx.doi.org/10.3892/ol.2023.14116

Ejemplares similares

Target concentration achievement for efficacy and safety of patients with osteosarcoma treated with high-dose methotrexate based on individual pharmacokinetics: A retrospective study
por: Nagamine, Ayumu, et al.
Publicado: (2022)

Blood Concentration of Cabazitaxel in a Patient Whose General Condition Worsened with Concomitant Use of Clarithromycin
por: Katsumi, Shigeaki, et al.
Publicado: (2023)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2013)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

The influence of Javanese turmeric (Curcuma xanthorrhiza) on the pharmacokinetics of warfarin in rats with single and multiple-dose studies
por: Rusdiana, Taofik, et al.
Publicado: (2021)

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
por: Lee, Matthew Man Pok, et al.
Publicado: (2023)

Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma
por: Tateai, Yoshikazu, et al.
Publicado: (2023)

Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma
por: Imakura, Takeshi, et al.
Publicado: (2021)

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
por: Sho, Takuya, et al.
Publicado: (2021)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3–ABCB1 Signaling in Hepatocellular Carcinoma
por: Hu, Beiyuan, et al.
Publicado: (2022)

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2019)

Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report
por: Takei, Shota, et al.
Publicado: (2023)

Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma
por: Matsumoto, Yukari, et al.
Publicado: (2022)

Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report
por: Kohya, Risako, et al.
Publicado: (2022)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2022)

Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma
por: Merle, Philippe
Publicado: (2023)

Rapid pleural effusion after discontinuation of lenvatinib in a patient with pleural metastasis from thyroid cancer
por: Uchida, Taisuke, et al.
Publicado: (2019)

Involvement of c‐Src in Carcinoma Cell Motility and Metastasis
por: Sakamoto, Michiie, et al.
Publicado: (2001)

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
por: Hiraoka, Atsushi, et al.
Publicado: (2020)

Differences in the Intestinal Microbiome Associated with Diarrhea during Lenvatinib Treatment for Hepatocellular Carcinoma
por: Inukai, Yosuke, et al.
Publicado: (2023)

Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2022)

Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment
por: Saeki, Issei, et al.
Publicado: (2020)

Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series
por: Ichimura, Takenori, et al.
Publicado: (2023)

Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells
por: Hou, Fang-jie, et al.
Publicado: (2019)

Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
por: Hirooka, Masashi, et al.
Publicado: (2018)

Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy
por: Shintani, Hiroshi, et al.
Publicado: (2021)

Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma
por: Rehman, Obaid, et al.
Publicado: (2021)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

Lenvatinib-Induced Destructive Thyroiditis in a Patient With Hepatocellular Carcinoma
por: Pandya, Anjani, et al.
Publicado: (2021)

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
por: He, Xiaoping, et al.
Publicado: (2022)

Lenvatinib-Induced Tumor Lysis Syndrome in Advanced Hepatocellular Carcinoma
por: Goyal, Manjeet Kumar, et al.
Publicado: (2023)

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Long, Jianwu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q1ointn1eodomb13lq49r324b2